Asymmetric Fc engineering for bispecific antibodies with reduced effector function

Download
  1. (PDF, 1 MB)
  2. Get@NRC: Asymmetric Fc engineering for bispecific antibodies with reduced effector function (Opens in a new window)
DOIResolve DOI: http://doi.org/10.3390/antib6020007
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleAntibodies
ISSN2073-4468
Volume6
Issue2
Article number7
Pages# of pages: 16
SubjectFc engineering; asymmetric bispecific antibody; ion exchange chromatography; knock-out effector function
AbstractAsymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector function. Although many solutions have been described in the literature to knockout effector function, to date all of them have involved the use of a specific antibody subtype (e.g., IgG2 or IgG4), or symmetric mutations in the lower hinge or CH2 domain of traditional homodimeric monospecific antibodies. In the context of a heterodimeric Fc, we describe novel asymmetric Fc mutations with reduced or silenced effector function in this article. These heteromultimeric designs contain asymmetric charged mutations in the lower hinge and the CH2 domain of the Fc. Surface plasmon resonance showed that the designed mutations display much reduced binding to all of the Fc gamma receptors and C1q. Ex vivo ADCC and CDC assays showed a consistent reduction in activity. Differential scanning calorimetry showed increased thermal stability for some of the designs. Finally, the asymmetric nature of the introduced charged mutations allowed for separation of homodimeric impurities by ion exchange chromatography, providing, as an added benefit, a purification strategy for the production of bispecific antibodies with reduced or silenced effector function.
Publication date
PublisherMDPI
LanguageEnglish
AffiliationHuman Health Therapeutics; National Research Council Canada
Peer reviewedYes
NPARC number23002203
Export citationExport as RIS
Report a correctionReport a correction
Record identifier7e4ff2b1-2a69-4d8e-829c-7a83b7531589
Record created2017-09-05
Record modified2017-09-05
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)